PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30935900-1	2020	INTRODUCTION AND OBJECTIVES: Neuron-specific enolase (NSE) is a prognostic marker in out-of-hospital cardiopulmonary arrest (OHCA) survivors treated with mild therapeutic hypothermia (MTH).	Plicamycin	184-187	enolase 2	Homo sapiens	29-52	
30935900-1	2020	INTRODUCTION AND OBJECTIVES: Neuron-specific enolase (NSE) is a prognostic marker in out-of-hospital cardiopulmonary arrest (OHCA) survivors treated with mild therapeutic hypothermia (MTH).	Plicamycin	184-187	enolase 2	Homo sapiens	54-57	
30935900-12	2020	CONCLUSIONS: Dynamic changes in NSE serum levels are good markers of hard clinical outcomes after an OHCA due to shockable rhythm in an MTH-treated cohort.	Plicamycin	136-139	enolase 2	Homo sapiens	32-35	
26681381-10	2017	CONCLUSION: Changes in the course of serum creatinine, urea and NSE levels within the first 72 h after OHCA could provide valuable additional information for the early assessment of the neurological prognosis in patients treated with MTH.	Plicamycin	234-237	enolase 2	Homo sapiens	64-67	
23836424-11	2014	CONCLUSION: In patients treated with MTH after OHCA changes in NSE are more suitable than its absolute serum levels for the prediction of poor neurologic outcome.	Plicamycin	37-40	enolase 2	Homo sapiens	63-66	
20403168-3	2010	Therefore we conducted a study investigating the association between NSE and neurological outcome in patients treated with MTH.	Plicamycin	123-126	enolase 2	Homo sapiens	69-72	
20403168-7	2010	RESULTS: NSE serum levels were significantly lower under MTH compared to NH in univariate analysis.	Plicamycin	57-60	enolase 2	Homo sapiens	9-12	
20403168-12	2010	Prospective multicentre trials are required to re-evaluate NSE cutoff values for the prediction of neurological outcome in patients treated with MTH.	Plicamycin	145-148	enolase 2	Homo sapiens	59-62